These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28295939)

  • 1. Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.
    Szatraj K; Szczepankowska AK; Chmielewska-Jeznach M
    J Appl Microbiol; 2017 Aug; 123(2):325-339. PubMed ID: 28295939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactic acid bacteria as live vaccines.
    Mercenier A; Müller-Alouf H; Grangette C
    Curr Issues Mol Biol; 2000 Jan; 2(1):17-25. PubMed ID: 11464916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination.
    Wyszyńska A; Kobierecka P; Bardowski J; Jagusztyn-Krynicka EK
    Appl Microbiol Biotechnol; 2015 Apr; 99(7):2967-77. PubMed ID: 25750046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.
    Wang M; Gao Z; Zhang Y; Pan L
    Appl Microbiol Biotechnol; 2016 Jul; 100(13):5691-701. PubMed ID: 27154346
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    LeCureux JS; Dean GA
    mSphere; 2018; 3(3):. PubMed ID: 29769376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.
    Levit R; Cortes-Perez NG; de Moreno de Leblanc A; Loiseau J; Aucouturier A; Langella P; LeBlanc JG; Bermúdez-Humarán LG
    Gut Microbes; 2022; 14(1):2110821. PubMed ID: 35960855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic expression of a model antigen with M Cell-Targeting moiety in lactic acid bacteria and implication of the mechanism as a mucosal vaccine via oral route.
    Oh SH; Kim SH; Jeon JH; Kim EB; Lee NK; Beck S; Choi YJ; Kang SK
    Vaccine; 2021 Jul; 39(30):4072-4081. PubMed ID: 34127296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.
    Bermúdez-Humarán LG; Kharrat P; Chatel JM; Langella P
    Microb Cell Fact; 2011 Aug; 10 Suppl 1(Suppl 1):S4. PubMed ID: 21995317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant lactic acid bacteria as promising vectors for mucosal vaccination.
    Qiao N; Du G; Zhong X; Sun X
    Exploration (Beijing); 2021 Oct; 1(2):20210026. PubMed ID: 37323212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes.
    Pouwels PH; Leer RJ; Shaw M; Heijne den Bak-Glashouwer MJ; Tielen FD; Smit E; Martinez B; Jore J; Conway PL
    Int J Food Microbiol; 1998 May; 41(2):155-67. PubMed ID: 9704864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant lactic acid bacteria as delivery vectors of heterologous antigens: the future of vaccination?
    Trombert A
    Benef Microbes; 2015; 6(3):313-24. PubMed ID: 25245573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of vaccine delivery vehicles based on lactic acid bacteria.
    Tarahomjoo S
    Mol Biotechnol; 2012 Jun; 51(2):183-99. PubMed ID: 21901278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers.
    Takahashi K; Orito N; Tokunoh N; Inoue N
    Appl Microbiol Biotechnol; 2019 Aug; 103(15):5947-5955. PubMed ID: 31175431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update.
    LeBlanc JG; Aubry C; Cortes-Perez NG; de Moreno de LeBlanc A; Vergnolle N; Langella P; Azevedo V; Chatel JM; Miyoshi A; Bermúdez-Humarán LG
    FEMS Microbiol Lett; 2013 Jul; 344(1):1-9. PubMed ID: 23600579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.
    Corbett M; Bogers WM; Heeney JL; Gerber S; Genin C; Didierlaurent A; Oostermeijer H; Dubbes R; Braskamp G; Lerondel S; Gomez CE; Esteban M; Wagner R; Kondova I; Mooij P; Balla-Jhagjhoorsingh S; Beenhakker N; Koopman G; van der Burg S; Kraehenbuhl JP; Le Pape A
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2046-51. PubMed ID: 18270165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J
    Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
    Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
    Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of lactic acid bacteria as mucosal vaccines].
    Bermúdez-Humarán LG; Langella P
    Rev Francoph Lab; 2009 Dec; 2009(417):79-89. PubMed ID: 32518601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization.
    Li HS; Piao DC; Jiang T; Bok JD; Cho CS; Lee YS; Kang SK; Choi YJ
    Vaccine; 2015 Apr; 33(16):1959-67. PubMed ID: 25738814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations.
    Medina E; Guzmán CA
    Vaccine; 2001 Feb; 19(13-14):1573-80. PubMed ID: 11166877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.